Related Experiment Video

Updated: Oct 23, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.8K

Impact of obesity on vascular calcification in patients with chronic kidney disease

Jana Uhlinova, Anne Kuudeberg, Alina Denissova

    Clinical Nephrology
    |August 17, 2021
    PubMed

    Insights

    Obesity is not an independent predictor of vascular calcification (VC) in chronic kidney disease (CKD) patients. However, VC was more pronounced in obese CKD patients with reduced kidney function, as assessed by three methods.

    Area of Science:

    • Nephrology
    • Cardiology
    • Vascular Biology

    Background:

    • Vascular calcification (VC) is a common complication in chronic kidney disease (CKD).
    • The role of obesity as an independent predictor of VC in CKD patients remains unclear.
    • Assessing VC using multiple methods is crucial for comprehensive evaluation.

    Purpose of the Study:

    • To compare vascular calcification (VC) in obese versus non-obese patients with chronic kidney disease (CKD).
    • To evaluate VC using three distinct measurement methods: abdominal aortic calcification (AAC), ankle-brachial index (ABI), and echocardiography.

    Main Methods:

    • 168 CKD patients were categorized by body mass index (BMI) into obese (≥ 30 kg/m²) and non-obese (< 30 kg/m²) groups.
    • Patients were further stratified by estimated glomerular filtration rate (eGFR) into subgroups with eGFR < 45 mL/min/1.73m² and eGFR ≥ 45 mL/min/1.73m².
    • VC was assessed using AAC, ABI, and echocardiography.

    Main Results:

    • Obese CKD patients were older. The prevalence of abdominal aortic calcification (AAC) was higher in patients with lower kidney function (eGFR < 45 mL/min/1.73m²).
    • Abnormal ankle-brachial index (ABI) values (≥ 1.3 or < 0.9) were more frequent in subgroups with lower kidney function.
    • Significant correlations were found between AAC and heart valve lesions, and between AAC and left ventricular hypertrophy (LVH).

    Conclusions:

    • Obesity is not an independent predictor of vascular calcification (VC) in chronic kidney disease (CKD) patients.
    • VC, evaluated by three methods, was more pronounced in obese CKD patients with lower kidney function.
    • These findings highlight the increased burden of VC in obese CKD patients with impaired renal function.
    Abstract

    More Related Videos

    Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

    Assessment of Vascular Function in Patients With Chronic Kidney Disease

    Published on: June 16, 2014

    16.4K
    A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro11:30

    A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

    Published on: June 2, 2022

    2.1K

    Related Concept Videos

    Chronic Kidney Disease II: Clinical Manifestations01:24

    Chronic Kidney Disease II: Clinical Manifestations

    Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
    182
    Chronic Kidney Disease I: Introduction01:25

    Chronic Kidney Disease I: Introduction

    Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
    277
    Chronic Kidney Disease III: Interprofessional Care01:28

    Chronic Kidney Disease III: Interprofessional Care

    Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
    148
    Urinary Tract Calculi IV: Nutrition Therapy and Prevention01:27

    Urinary Tract Calculi IV: Nutrition Therapy and Prevention

    Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
    166
    Drug Dosing: Obese Patients01:21

    Drug Dosing: Obese Patients

    In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
    30
    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
    40